News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Roche (RHHBY)'s Avastin Rejected by U.K. Agency, National Institute for Clinical Excellence (NICE) for Colorectal Cancer


12/15/2010 7:44:12 AM

Bloomberg -- Roche Holding AG’s Avastin failed to win the backing of the U.K. National Institute for Health and Clinical Excellence for use in combination with chemotherapy against colorectal cancer that has spread. The drug’s benefits don’t justify the cost, the agency said today in an e-mailed statement. The decision, which confirms preliminary rulings by NICE, is final, the agency said.

Read at Bloomberg
Read at News Release
Read at Wall Street Journal


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES